The Hematology/Oncology Pharmacy Association has helped establish practical guidance for Investigational Services metrics and site utilization.

The metrics subgroup of the HOPA Investigational drug services (IDS) special interest group recently conducted a survey-based project to help establish practical guidance for IDS metrics and site utlity. Three surveys were sent to HOPA IDS professionals to document how metrics were currently gathered at various sites, categorize and define additional approaches, and create a list of recommended metrics for every IDS site to track. The recommended metrics can serve as a basis for standardization and benchmarking for sites mired in the complexity of research protocols.

The results have been published in the American Journal of Health-Systems Pharmacy.


Authors: Molly Schmidt, PharmD, BCPS, BCOP, CSP; Lisa Janssen Carlson, PharmD, BCOP; Jennifer Murphy, PharmD, BCOP, Sapna R Amin, PharmD, BCOP; Robin Lockhorst, PharmD, BCOP, BCPS; and Kyle Luedtke, PharmD

Read the abstract

Digital medical illustration of a bladder
Tools and Resources Drug Updates

Pharmacist's Application
to Practice: Nogapendekin
alfa inbakicept-pmln

Devan Parker, PharmD, PGY2 Oncology Pharmacy Resident and Juliana Leedy, PharmD, MS, Clinical Oncology Pharmacist, The University of Alabama at Birmingham (UAB) Hospital, Birmingham, Alabama writes about nogapendekin alfa inbakicept-pmln.

X-ray of brain with desmoid tumors
Tools and Resources Drug Updates

Pharmacist’s Application to Practice: Nirogacestat (Ogsiveo)

Brooke Lochridge, PharmD ,PGY-2 Oncology Pharmacy Resident, of Tristar Centennial Medical Center, Nashville, TN, and Colleen McCabe, PharmD, BCOP, Oncology Clinical Specialist, Sarcoma & Melanoma from Vanderbilt University Medical Center, Nashville, TN w

high-risk neuroblastoma
Tools and Resources Drug Updates

Pharmacist’s Application to Practice: Eflornithine for High-Risk Neuroblastoma

Taylor Gullickson, PharmD, PGY1 Pharmacy Resident and Alexis Kuhn, PharmD, BCOP, Pediatric Oncology Pharmacist, from Mayo Clinic Rochester, Minnesota write about Eflornithine for High-Risk Neuroblastoma.